Clinical efficacy and safety of bicalutamide combine with goserelin in the treatment of advanced prostate cancer
10.13699/j.cnki.1001-6821.2016.03.010
- VernacularTitle:比卡鲁胺联合戈舍瑞林治疗晚期前列腺癌的临床疗效及安全性评价
- Author:
Kuang PANG
1
;
Ze-Guang ZHOU
;
Ying-Fan HUANG
;
Cheng-Bei LIU
;
Wei XU
Author Information
1. 玉林市第一人民医院 泌尿外科
- Keywords:
bicalutamide;
goserelin;
prostate cancer;
clinical efficacy;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2016;(3):224-226
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of bi-calutamide combine with goserelin in the treatment of advanced prostate cancer.Methods Fifty cases of advanced prostate cancer patients were randomly divided into treatment group (25 cases) and control group (25 cases).Treatment group was given oral bicalutamide 50 mg, qd +sub-cutaneous goserelin 3.6 mg, once 4 weeks, a monthly review of serum prostate-specific antigen ( PSA ) content , when the serum PSA <0.2 ng· mL-1, disabled two drugs, when PSA>4 ng· mL-1, begin a new round of treatment.Control group was given the continuous dosing , the same dosage and usage as the treatment group.The course of treatment for two groups was 12 months.Comparison of the clinical efficacy , serum PSA value and adverse drug reactions.Results After 6, 9, 12 months of treatment , the clinical efficacy of treatment group was significantly higher than that of control group (P<0.05).After 3, 6, 9, 12 months of treatment , the serum PSA value was significantly lower than that of before treatment ( P<0.05 ) , and there was no significant difference in serum PSA between the two groups at each time point ( P>0.05 ).The main adverse drug reactions of the two groups were the castration syndrome , blood vessel contraction , osteoporosis , and liver toxicity, and the incidence rate of adverse drug reactions were not statistically different between the two groups ( P>0.05 ).Conclusion The clinical efficacy of intermittent administration for bicalutamide combined with goserelin in the treatment of advanced prostate cancer was significantly better than the continuous dosing , without increasing the incidence of adverse drug reactions.
